Haemonetics Co. (NYSE:HAE) Director Ronald Merriman sold 17,471 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $40.33, for a total transaction of $704,605.43. Following the completion of the transaction, the director now directly owns 24,925 shares of the company’s stock, valued at approximately $1,005,225.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Haemonetics Co. (NYSE:HAE) traded up 1.35% during trading on Wednesday, reaching $40.67. 246,898 shares of the company’s stock traded hands. The company has a 50 day moving average price of $41.37 and a 200-day moving average price of $39.83. The company’s market cap is $2.11 billion. Haemonetics Co. has a 12-month low of $27.53 and a 12-month high of $43.62.

Haemonetics (NYSE:HAE) last announced its quarterly earnings results on Monday, May 8th. The medical instruments supplier reported $0.39 EPS for the quarter, beating the consensus estimate of $0.37 by $0.02. Haemonetics had a return on equity of 10.51% and a net margin of 1.79%. The company had revenue of $228.10 million for the quarter, compared to the consensus estimate of $215.06 million. During the same quarter last year, the company posted $0.37 earnings per share. The company’s revenue for the quarter was down 5.9% compared to the same quarter last year. On average, equities research analysts forecast that Haemonetics Co. will post $1.60 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Haemonetics Co. (HAE) Director Sells $704,605.43 in Stock” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.americanbankingnews.com/2017/05/24/haemonetics-co-hae-director-sells-704605-43-in-stock.html.

Institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. bought a new position in shares of Haemonetics during the first quarter valued at approximately $179,000. State of Alaska Department of Revenue increased its position in shares of Haemonetics by 2.3% in the first quarter. State of Alaska Department of Revenue now owns 5,740 shares of the medical instruments supplier’s stock valued at $232,000 after buying an additional 130 shares during the period. Trexquant Investment LP bought a new position in shares of Haemonetics during the fourth quarter valued at approximately $269,000. AXA bought a new position in shares of Haemonetics during the first quarter valued at approximately $292,000. Finally, Kirr Marbach & Co. LLC IN increased its position in shares of Haemonetics by 1.1% in the first quarter. Kirr Marbach & Co. LLC IN now owns 7,230 shares of the medical instruments supplier’s stock valued at $293,000 after buying an additional 80 shares during the period. Institutional investors own 99.43% of the company’s stock.

A number of equities analysts recently commented on HAE shares. Barrington Research downgraded shares of Haemonetics from an “outperform” rating to a “market perform” rating in a research note on Tuesday, February 7th. Zacks Investment Research raised shares of Haemonetics from a “sell” rating to a “hold” rating in a research note on Tuesday, April 11th. TheStreet raised shares of Haemonetics from a “c” rating to a “b-” rating in a research note on Thursday, April 13th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $42.00 price objective on shares of Haemonetics in a research note on Monday, May 8th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $35.83.

Haemonetics Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

12 Month Chart for NYSE:HAE

Receive News & Ratings for Haemonetics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Co. and related companies with MarketBeat.com's FREE daily email newsletter.